Long shot Phase 3 trial finds semaglutide did not deliver a statistically significant reduction in Alzheimer’s progression.
Pharma giant Novo Nordisk’s effort to repurpose semaglutide (better known as diabetes and weight loss drugs Ozempic and Wegovy) for early-stage Alzheimer’s has concluded with two large Phase 3 studies failing to show a measurable effect on disease progression. Despite clearly being a long shot for the company, the results are a setback for one of the most closely watched programs exploring GLP-1–based therapies beyond metabolic disease.
Ever since we first suggested back in 2023 that GLP-1 therapies may turn out to be longevity drugs, the evidence has continued to mount for their potential benefits beyond weight loss, with neuroprotection a significant area of interest. Indeed, Novo Nordisk pursued its Alzheimer’s program based on converging preclinical and observational evidence suggesting that GLP-1 receptor agonists might influence neurodegenerative processes.
“Based on the significant unmet need in Alzheimer’s disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” said Novo CSO Martin Holst Lange. “We are proud to have conducted two well-controlled phase 3 trials in Alzheimer’s disease that meet the highest standards of research and rigorous methodology.”
The company reported top-line results from the two-year primary analysis of its evoke and evoke+ trials, which together enrolled 3,808 adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease and confirmed amyloid positivity. Investigators assessed whether semaglutide could slow decline using a widely used composite measure of cognition and function across key domains.
Semaglutide did not demonstrate superiority over placebo on the trial’s primary outcome, however Novo reported that the treatment produced favorable shifts in Alzheimer’s-related biomarkers, but that these “did not translate into a delay of disease progression.”
“While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities,” said Lange.
Novo’s results underscore the ongoing challenge of translating mechanistic and preclinical promise into clinical benefit in neurodegenerative disease. It should be noted that beyond direct neurobiological effects, GLP-1 agonists also influence cardiometabolic factors that shape long-term brain health. By improving glycemic control, reducing weight, lowering insulin resistance and modestly decreasing blood pressure, GLP-1s may address vascular risks associated with small-vessel disease and cognitive decline. Whether these benefits can meaningfully alter the trajectory of neurodegenerative and other age-related diseases remains an open question, however both Lilly and Novo execs at this year’s ARDD conference openly referred to GLP-1s as potential longevity drugs.
